期刊文献+

5%咪喹莫特与0.5%鬼臼毒素治疗尖锐湿疣的成本-效果分析 被引量:5

Cost-effectiveness Analysis of 5% Imiquimod and 0.5% Podophyllotoxin in the Treatment of Condyloma Acuminatum
下载PDF
导出
摘要 目的 :评价5 %咪喹莫特与0 5 %鬼臼毒素治疗尖锐湿疣的成本 -效果。方法 :收集1966年~2003年间有关咪喹莫特与鬼臼毒素治疗尖锐湿疣的随机双盲安慰剂对照临床研究文献 ,比较两种药物的临床疗效和不良反应 ,并作成本 -效果分析。结果 :咪喹莫特与鬼臼毒素治疗尖锐湿疣的治愈率分别为48 48 %、46 62 % ,无显著性差异 (P>0 05)。咪喹莫特最常见的不良反应为红斑、糜烂、瘙痒和表皮脱落、结痂、水肿 ;鬼臼毒素最常见的不良反应为灼热、炎症、糜烂、疼痛、瘙痒、出血。二者比较 ,鬼臼毒素不良反应发生率较高 ,也较严重。咪喹莫特与鬼臼毒素治疗尖锐湿疣的成本 -效果比分别为36 88、8 15。结论 :咪喹莫特与鬼臼毒素治疗尖锐湿疣具有相似的疗效 ,虽然鬼臼毒素成本 -效果比较低 ,但其不良反应却较多和较严重。 OBJECTIVE:To evaluate the cost-effectiveness ratios of5%imiquimod and0.5%podophyllotoxin in the treatment of condyloma acuminatum.METHODS:The reports on imiquimod and podophyllotoxin in the treatment of condyloˉma acuminatum with randomized,double-blind and placebo-controlled design,published from1966to2003,were collectˉed.The therapeutic effects and ADRs of two drugs were compared and conducted with cost-effectiveness analysis.RESULTS:The clinical cure rates of imiquimod and podophyllotoxin were48.48%and46.62%respectively with no statistically significant differences(P>0.05).The most common adverse reactions of imiquimod were erythema,erosion,itching,excoriation,scabbing and oedema,those of podophyllotoxin were burning sensation,inflammation,erosion,pain,itching and bleeding.The incidence of ADR of podophyllotoxin was higher.Cost-effectiveness analysis indicated that the C/E of imiquimod and podophyllotoxin was36.88and8.15respectively.CONCLUSION:Imiquimod and podophyllotoxin possessed similar curative effect on condyloˉma acuminatum,but the cost and C/E of podophyllotoxin were lower.At the same time,podophyllotoxin had more serious adˉverse reactions.
出处 《中国药房》 CAS CSCD 2004年第12期735-737,共3页 China Pharmacy
关键词 咪喹莫特 鬼臼毒素 尖锐湿疣 循征医学 文献荟萃分析 成本-效果分析 Imiquimod podophyllotoxin condyloma acuminatum evidence-based medicine meta-analysis cost-effecˉtiveness analysis
  • 相关文献

参考文献24

  • 1Cates WJ. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Am- erican Social Health Association Panel[J]. Sex Transm Dis, 1999, 26( 4 Suppl): S2.
  • 2Hughes G, Simms I, Rogers PA, et al. New cases seen at genito urinary medicine clinics: England 1997[J]. Commun Dis Rep CDR, 1998, 8( 7 Suppl): 1.
  • 3Koutsky L. Epidemiology of genital papillomavirus inf- ection[J]. Am J Med, 1997, 102( 5A): 3.
  • 4Beutner KR, Ferenczy A. Therapeutic approaches to ge- nital warts[J]. Am J Med, 1997, 102( 5A): 28.
  • 5Ferenczy A, Mitao M, Nagai N, et al. Latent papilloma- virus and recurring genital warts[J]. N Engl J Med, 1985, 313( 13): 784.
  • 6Czelusta AJ, Evans T, Arany I, et al. Aguide to immun- otherapy of genital warts: focus on interferon and imiquimod[J]. Bio Drugs, 1999, 11( 5): 319.
  • 7Tyring SK, Arany I, Stanley MA, et al. A randomised, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod[J]. J Infect Dis, 1998, 178( 2): 551.
  • 8Coleman N, Birley HDL, Renton AM, et al. Immunolog- ical events in regressing genital warts[J]. Am J Clin Pathol, 1994, 102( 6): 768.
  • 9Sauder DN, Skinner RB, Fox TL, et al. Topical imiqui- mod 5% cream as an effective treatment for external genital and perianal warts in different patient populations[J]. Sex Transm Dis, 2003, 30( 2): 124.
  • 10Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiqui- mod, a patient- applied immune- response modifier for treatment of external genital warts[J]. Antimicrob Ag- ents Chemother, 1998, 42( 4): 789.

同被引文献53

引证文献5

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部